These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1614 related items for PubMed ID: 32197467

  • 21. Low expression of PDK1 inhibits renal cell carcinoma cell proliferation, migration, invasion and epithelial mesenchymal transition through inhibition of the PI3K-PDK1-Akt pathway.
    Zhou WM, Wu GL, Huang J, Li JG, Hao C, He QM, Chen XD, Wang GX, Tu XH.
    Cell Signal; 2019 Apr; 56():1-14. PubMed ID: 30465826
    [Abstract] [Full Text] [Related]

  • 22. Effects of orexin A on glucose metabolism in human hepatocellular carcinoma in vitro via PI3K/Akt/mTOR-dependent and -independent mechanism.
    Liu Y, Zhao Y, Guo L.
    Mol Cell Endocrinol; 2016 Jan 15; 420():208-16. PubMed ID: 26549689
    [Abstract] [Full Text] [Related]

  • 23. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.
    Zhang Z, Zhu J, Huang Y, Li W, Cheng H.
    Diagn Pathol; 2018 Nov 03; 13(1):85. PubMed ID: 30390677
    [Abstract] [Full Text] [Related]

  • 24. M2‑like tumour‑associated macrophage‑secreted IGF promotes thyroid cancer stemness and metastasis by activating the PI3K/AKT/mTOR pathway.
    Lv J, Liu C, Chen FK, Feng ZP, Jia L, Liu PJ, Yang ZX, Hou F, Deng ZY.
    Mol Med Rep; 2021 Aug 03; 24(2):. PubMed ID: 34184083
    [Abstract] [Full Text] [Related]

  • 25. miR-300 regulates the epithelial-mesenchymal transition and invasion of hepatocellular carcinoma by targeting the FAK/PI3K/AKT signaling pathway.
    Wang R, Yu Z, Chen F, Xu H, Shen S, Chen W, Chen L, Su Q, Zhang L, Bi J, Zeng W, Li W, Huang X, Wang Q.
    Biomed Pharmacother; 2018 Jul 03; 103():1632-1642. PubMed ID: 29864952
    [Abstract] [Full Text] [Related]

  • 26. [Ponatinib inhibits the proliferation of SNU-449 human hepatocellular cancer cells and blocks MAPK and PDK1/AKT/mTOR signaling pathways].
    Liu C, Pei J, Mu X, Yu B, Gong T, Liang W.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 May 03; 38(5):425-431. PubMed ID: 35603651
    [Abstract] [Full Text] [Related]

  • 27. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
    Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, Jücker M.
    Mol Cancer; 2012 Nov 20; 11():85. PubMed ID: 23167739
    [Abstract] [Full Text] [Related]

  • 28. Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma.
    Liao J, Jin H, Li S, Xu L, Peng Z, Wei G, Long J, Guo Y, Kuang M, Zhou Q, Peng S.
    J Exp Clin Cancer Res; 2019 Nov 06; 38(1):454. PubMed ID: 31694662
    [Abstract] [Full Text] [Related]

  • 29. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
    Toh TB, Lim JJ, Hooi L, Rashid MBMA, Chow EK.
    J Hepatol; 2020 Jan 06; 72(1):104-118. PubMed ID: 31541681
    [Abstract] [Full Text] [Related]

  • 30. PKI-587 enhances radiosensitization of hepatocellular carcinoma by inhibiting the PI3K/AKT/mTOR pathways and DNA damage repair.
    Xie Y, Liu C, Zhang Y, Li A, Sun C, Li R, Xing Y, Shi M, Wang Q.
    PLoS One; 2021 Jan 06; 16(10):e0258817. PubMed ID: 34665844
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. SNRPD1 inhibition suppresses the proliferation of hepatocellular carcinoma and promotes autophagy through the PI3K/AKT/mTOR/4EBP1 pathway.
    Wang H, Chen M, Yang C, Hu H, Jiang Y, Yang F, Lv L.
    Arch Biochem Biophys; 2023 Jul 15; 743():109661. PubMed ID: 37268273
    [Abstract] [Full Text] [Related]

  • 33. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH, Choi MJ, Hong S, Lee H, Hong SW, Zheng HM, Lee HS, Hong S, Hong SS.
    Cancer Lett; 2012 Mar 28; 316(2):187-95. PubMed ID: 22182943
    [Abstract] [Full Text] [Related]

  • 34. Hydrogen sulfide promotes autophagy of hepatocellular carcinoma cells through the PI3K/Akt/mTOR signaling pathway.
    Wang SS, Chen YH, Chen N, Wang LJ, Chen DX, Weng HL, Dooley S, Ding HG.
    Cell Death Dis; 2017 Mar 23; 8(3):e2688. PubMed ID: 28333142
    [Abstract] [Full Text] [Related]

  • 35. Targeting the Epigenetic Non-Coding RNA MALAT1/Wnt Signaling Axis as a Therapeutic Approach to Suppress Stemness and Metastasis in Hepatocellular Carcinoma.
    Chang HL, Bamodu OA, Ong JR, Lee WH, Yeh CT, Tsai JT.
    Cells; 2020 Apr 20; 9(4):. PubMed ID: 32326045
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Targeting PI3K/Akt/mTOR Pathway Identifies Differential Expression and Functional Role of IL8 in Liver Cancer Stem Cell Enrichment.
    Kahraman DC, Kahraman T, Cetin-Atalay R.
    Mol Cancer Ther; 2019 Nov 20; 18(11):2146-2157. PubMed ID: 31439713
    [Abstract] [Full Text] [Related]

  • 38. MiR-20a Induces Cell Radioresistance by Activating the PTEN/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma.
    Zhang Y, Zheng L, Ding Y, Li Q, Wang R, Liu T, Sun Q, Yang H, Peng S, Wang W, Chen L.
    Int J Radiat Oncol Biol Phys; 2015 Aug 01; 92(5):1132-1140. PubMed ID: 26031366
    [Abstract] [Full Text] [Related]

  • 39. MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway.
    Xu Q, Liu X, Liu Z, Zhou Z, Wang Y, Tu J, Li L, Bao H, Yang L, Tu K.
    Mol Cancer; 2017 Jun 12; 16(1):103. PubMed ID: 28606154
    [Abstract] [Full Text] [Related]

  • 40. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
    Zhang DM, Liu JS, Deng LJ, Chen MF, Yiu A, Cao HH, Tian HY, Fung KP, Kurihara H, Pan JX, Ye WC.
    Carcinogenesis; 2013 Jun 12; 34(6):1331-42. PubMed ID: 23393227
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 81.